CT Imaging for Guiding PA-TACE for HCC

Sponsor

Zhujiang Hospital (Other)

Overall Status

Recruiting

CT.gov ID

NCT06156748

Collaborator

(none)

1,488

Enrollment

Location

Anticipated Duration (Months)

19.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criterion for the selection of candidates are lacking. The present study aimed to evaluate whether CT imaging can provide more value for predicting benefit from PA-TACE.

Condition or Disease	Intervention/Treatment	Phase
Carcinoma, Hepatocellular	Procedure: postoperative adjuvant transarterial chemoembolization

Study Design

Study Type:

Observational

Anticipated Enrollment :

1488 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

CT Imaging for Guiding Postoperative Adjuvant Transarterial Chemoembolization for Hepatocellular Carcinoma

Actual Study Start Date :

Oct 1, 2019

Anticipated Primary Completion Date :

Sep 30, 2024

Anticipated Study Completion Date :

Dec 31, 2025

Arms and Interventions

Arm	Intervention/Treatment
Hepatectomy alone	Procedure: postoperative adjuvant transarterial chemoembolization HCC patients received hepatectomy and PA-TACE.
PA-TACE

Arm

Intervention/Treatment

Hepatectomy alone

Procedure: postoperative adjuvant transarterial chemoembolization

HCC patients received hepatectomy and PA-TACE.

PA-TACE

Outcome Measures

Primary Outcome Measures

Overall survival [the date of hepatectomy to the last follow-up or until death, whichever came first, assessed up to 120 months.]
Overall survival was calculated from the date of hepatectomy to the last follow-up or until death, whichever came first.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

CT scans acquired no more than one month before surgery
Confirmation of HCC diagnosis by pathological examination
Curative surgical resection

Exclusion Criteria:

Prior antitumor treatment
Macrovascular thrombosis or metastasis
Perioperative mortality
Unqualified image artifacts
Tumor rupture
MVI status not reported

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	ZhuJiang Hospital of Southern Medical University	Guangzhou	Guangdong	China	510280

Sponsors and Collaborators

Zhujiang Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Quan Xianyue, Academic Head of Department of Radiology, Zhujiang Hospital

ClinicalTrials.gov Identifier:

NCT06156748

Other Study ID Numbers:

2019-KY-021-01

First Posted:

Dec 5, 2023

Last Update Posted:

Dec 5, 2023

Last Verified:

Nov 1, 2023

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Quan Xianyue, Academic Head of Department of Radiology, Zhujiang Hospital

Carcinoma, Hepatocellular

Additional relevant MeSH terms:

Carcinoma

Carcinoma, Hepatocellular

Study Results

No Results Posted as of Dec 5, 2023